{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:58:26Z","timestamp":1767117506771},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T00:00:00Z","timestamp":1334793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11060-012-0872-x","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T15:47:06Z","timestamp":1334764026000},"page":"105-114","source":"Crossref","is-referenced-by-count":38,"title":["Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors"],"prefix":"10.1007","volume":"109","author":[{"given":"Eric M.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"D\u00f3sa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie J.","family":"Nazemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seymur","family":"Gahramanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwyn E.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Neuwelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,19]]},"reference":[{"key":"872_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/neuonc\/noq202","volume":"13","author":"DA Haas-Kogan","year":"2011","unstructured":"Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE (2011) Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 13:298\u2013306. doi: 10.1093\/neuonc\/noq202","journal-title":"Neuro Oncol"},{"key":"872_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1748-717X-5-9","volume":"5","author":"C Meyzer","year":"2010","unstructured":"Meyzer C, Dhermain F, Ducreux D, Habrand JL, Varlet P, Sainte-Rose C, Dufour C, Grill J (2010) A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI. Radiat Oncol 5:9. doi: 10.1186\/1748-717X-5-9","journal-title":"Radiat Oncol"},{"key":"872_CR3","unstructured":"US Food and Drug Administration. FDA Application: Ferumoxytol. Available at http:\/\/wwwaccessdatafdagov\/scripts\/opdlisting\/oopd\/OOPD_Results_2cfm?Index_Number=338411 . Accessed 17 May 2011"},{"key":"872_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/neuonc\/noq172","volume":"13","author":"E Dosa","year":"2011","unstructured":"Dosa E, Guillaume DJ, Haluska M, Lacy CA, Hamilton BE, Njus JM, Rooney WD, Kraemer DF, Muldoon LL, Neuwelt EA (2011) Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol 13:251\u2013260. doi: 10.1093\/neuonc\/noq172","journal-title":"Neuro Oncol"},{"key":"872_CR5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1227\/01.NEU.0000255350.71700.37","volume":"60","author":"EA Neuwelt","year":"2007","unstructured":"Neuwelt EA, Varallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, Nesbit G, Stevens A, Jerosch-Herold M, Jacobs PM, Hoffman JM (2007) The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 60:601\u2013611 (discussion 611\u2013602)","journal-title":"Neurosurgery"},{"key":"872_CR6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/jcbfm.2008.162","volume":"29","author":"CG Varallyay","year":"2009","unstructured":"Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA (2009) Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 29:853\u2013860. doi: 10.1038\/jcbfm.2008.162","journal-title":"J Cereb Blood Flow Metab"},{"key":"872_CR7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijrobp.2009.10.072","volume":"79","author":"S Gahramanov","year":"2011","unstructured":"Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG, Njus JM, Haluska M, Neuwelt EA (2011) Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 79:514\u2013523. doi: 10.1016\/j.ijrobp.2009.10.072","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR8","doi-asserted-by":"crossref","unstructured":"Gahramanov S, Muldoon LL, Li X, Neuwelt EA Improved Perfusion MR Imaging Assessment of Intracerebral Tumor Blood Volume and Antiangiogenic Therapy Efficacy in a Rat Model with Ferumoxytol. Radiology 261:796\u2013804. doi: 10.1148\/radiol.11103503","DOI":"10.1148\/radiol.11103503"},{"key":"872_CR9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jmri.20045","volume":"19","author":"HA Haroon","year":"2004","unstructured":"Haroon HA, Buckley DL, Patankar TA, Dow GR, Rutherford SA, Baleriaux D, Jackson A (2004) A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 19:527\u2013536. doi: 10.1002\/jmri.20045","journal-title":"J Magn Reson Imaging"},{"key":"872_CR10","first-page":"2455","volume":"26","author":"TF Patankar","year":"2005","unstructured":"Patankar TF, Haroon HA, Mills SJ, Baleriaux D, Buckley DL, Parker GJ, Jackson A (2005) Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? A. AJNR Am J Neuroradiol 26:2455\u20132465","journal-title":"AJNR Am J Neuroradiol"},{"key":"872_CR11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3174\/ajnr.A1844","volume":"31","author":"SJ Mills","year":"2010","unstructured":"Mills SJ, Soh C, Rose CJ, Cheung S, Zhao S, Parker GJ, Jackson A (2010) Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging-derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 31:549\u2013553. doi: 10.3174\/ajnr.A1844","journal-title":"AJNR Am J Neuroradiol"},{"key":"872_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453\u2013461. doi: 10.1016\/S1470-2045(08)70125-6","journal-title":"Lancet Oncol"},{"key":"872_CR13","unstructured":"CTEP (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE)"},{"key":"872_CR14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1148\/radiol.2243011014","volume":"224","author":"SG Wetzel","year":"2002","unstructured":"Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL, Pierce SD, Xue X (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224:797\u2013803","journal-title":"Radiology"},{"key":"872_CR15","doi-asserted-by":"crossref","unstructured":"Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223\u2013232 doi: 10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S [pii]","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S"},{"key":"872_CR16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3171\/jns.1990.72.4.0572","volume":"72","author":"AE Evans","year":"1990","unstructured":"Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL et al (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572\u2013582. doi: 10.3171\/jns.1990.72.4.0572","journal-title":"J Neurosurg"},{"key":"872_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(04)01424-X","volume":"5","author":"RJ Gilbertson","year":"2004","unstructured":"Gilbertson RJ (2004) Medulloblastoma: signalling a change in treatment. Lancet Oncol 5:209\u2013218. doi: 10.1016\/S1470-2045(04)01424-X","journal-title":"Lancet Oncol"},{"key":"872_CR18","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"AA Brandes","year":"2008","unstructured":"Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192\u20132197. doi: 10.1200\/JCO.2007.14.8163","journal-title":"J Clin Oncol"},{"key":"872_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/jcbfm.2009.192","volume":"30","author":"JS Weinstein","year":"2010","unstructured":"Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, Muldoon LL, Neuwelt EA (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30:15\u201335. doi: 10.1038\/jcbfm.2009.192","journal-title":"J Cereb Blood Flow Metab"},{"key":"872_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdm510","volume":"19","author":"M Benesch","year":"2008","unstructured":"Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C (2008) Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 19:807\u2013813. doi: 10.1093\/annonc\/mdm510","journal-title":"Ann Oncol"},{"key":"872_CR21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.ijrobp.2008.12.032","volume":"75","author":"AK Liu","year":"2009","unstructured":"Liu AK, Macy ME, Foreman NK (2009) Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 75:1148\u20131154. doi: 10.1016\/j.ijrobp.2008.12.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"872_CR22","first-page":"409","volume":"27","author":"S Cha","year":"2006","unstructured":"Cha S, Yang L, Johnson G, Lai A, Chen MH, Tihan T, Wendland M, Dillon WP (2006) Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 27:409\u2013417","journal-title":"AJNR Am J Neuroradiol"},{"key":"872_CR23","first-page":"853","volume":"27","author":"SJ Mills","year":"2006","unstructured":"Mills SJ, Patankar TA, Haroon HA, Baleriaux D, Swindell R, Jackson A (2006) Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 27:853\u2013858","journal-title":"AJNR Am J Neuroradiol"},{"key":"872_CR24","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","volume":"16","author":"PR Lockman","year":"2010","unstructured":"Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664\u20135678. doi: 10.1158\/1078-0432.CCR-10-1564","journal-title":"Clin Cancer Res"},{"key":"872_CR25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jmri.20182","volume":"20","author":"JU Harrer","year":"2004","unstructured":"Harrer JU, Parker GJ, Haroon HA, Buckley DL, Embelton K, Roberts C, Baleriaux D, Jackson A (2004) Comparative study of methods for determining vascular permeability and blood volume in human gliomas. J Magn Reson Imaging 20:748\u2013757. doi: 10.1002\/jmri.20182","journal-title":"J Magn Reson Imaging"},{"key":"872_CR26","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/mrm.22335","volume":"63","author":"GZ Ferl","year":"2010","unstructured":"Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE (2010) An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. Magn Reson Med 63:1366\u20131375. doi: 10.1002\/mrm.22335","journal-title":"Magn Reson Med"},{"key":"872_CR27","first-page":"1975","volume":"27","author":"M Law","year":"2006","unstructured":"Law M, Young R, Babb J, Rad M, Sasaki T, Zagzag D, Johnson G (2006) Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 27:1975\u20131982","journal-title":"AJNR Am J Neuroradiol"},{"key":"872_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21656","volume":"85","author":"M Lu","year":"2010","unstructured":"Lu M, Cohen MH, Rieves D, Pazdur R (2010) FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85:315\u2013319. doi: 10.1002\/ajh.21656","journal-title":"Am J Hematol"},{"key":"872_CR29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2214\/AJR.10.5992","volume":"197","author":"BE Hamilton","year":"2011","unstructured":"Hamilton BE, Nesbit GM, Dosa E, Gahramanov S, Rooney B, Nesbit EG, Raines J, Neuwelt EA (2011) Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. Am J Roentgenol 197:981\u2013988. doi: 10.2214\/AJR.10.5992","journal-title":"Am J Roentgenol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-012-0872-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0872-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T11:28:20Z","timestamp":1713871700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-012-0872-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s11060-012-0872-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}